
ADMA Biologics Faces Class Action Over Alleged Disclosure Failures
Investors who lost more than $100,000 in ADMA Biologics securities between August 2024 and March 2026 face an August 10 deadline to file as lead plaintiffs. The lawsuit, pending in New Jersey, alleges the company misled shareholders regarding its internal controls, revenue practices, and undisclosed related-party transactions.






















